Sareum Holdings (GB:SAR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sareum Holdings PLC, a biotech firm specializing in kinase inhibitors for cancer and autoimmune diseases, has issued new ordinary shares following a warrant exercise by RiverFort Global Opportunities. This warrant exercise has generated £110,698.60 for the company, with no further warrants held by RiverFort. The newly issued shares are expected to be admitted for trading on the AIM segment of the London Stock Exchange.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
